Olanzapine in long-term treatment for bipolar disorder

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Cipriani, Andrea ^a   Rendell, Jennifer M ^b   Geddes, John ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antimanic agents adverse effects; *therapeutic use ; Benzodiazepines adverse effects; *therapeutic use ; Bipolar disorder *drug therapy ; Humans; Lithium compounds therapeutic use ; Randomized controlled trials as topic; Recurrence; Valproic acid therapeutic use

Indexed keywords

ANTICONVULSIVE AGENT; BENZATROPINE MESILATE; BENZODIAZEPINE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; GABAPENTIN; LAMOTRIGINE; LITHIUM; LORAZEPAM; MOOD STABILIZER; OLANZAPINE; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; TRIHEXYPHENIDYL; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

AGITATION; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANXIETY; APATHY; APPETITE; ASTHENIA; BACKACHE; BIPOLAR DISORDER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; DYSKINESIA; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERSOMNIA; INSOMNIA; LIVER FUNCTION; MAINTENANCE THERAPY; MONOTHERAPY; NAUSEA; NERVOUSNESS; PAIN; PARKINSONISM; PHARYNGITIS; PROLACTIN BLOOD LEVEL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RECTUM DISEASE; RELAPSE; REVIEW; RHINITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; THOUGHT DISORDER; THROMBOCYTE COUNT; TREMOR; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 67650768089     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004367.pub2     Document Type: Review

References (48)

1. Altamura AC, Russo M, Vismara S, Mundo E. Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder. J Clin Psychopharmacol 2004;24:454-456
2. * Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW. Olanzapine versus divalproex sodiumfor the treatment of acutemania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003; Vol.160:1263-1271
3. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. British Journal of Psychiatry. 2004; Vol.184:337-345
4. * Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. American Journal of Psychiatry. 2005; Vol.162:1281-1290
5. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. American Journal of Psychiatry 2006;163:247-256
6. Ghaemi SN. New treatments for bipolar disorder: the role of atypical neuroleptic agents. Journal of Clinical Psychiatry 2000;61 Suppl 14: 33-42.
7. Nemeroff CB. An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. Journal of Clinical Psychiatry 2000;61 Suppl 13:19-25.
8. Tohen M, Zarate CA Jr. Antipsychotic agents and bipolar disorder. Journal of Clinical Psychiatry 1998;59 Suppl 1:38-48.
9. Weizman R, Weizman A. Use of atypical antipsychotics in mood disorders. Curr Opin Investig Drugs 2001;2:940-945
10. Yatham LN. The role of novel antipsychotics in bipolar disorders. Journal of Clinical Psychiatry 2002;63 Suppl 3:10-14.
11. Abood Z, Sharkey A, Webb M, Kelly A Gill, M. Are patients with bipolar affective disorder socially disadvantaged? A comparison with a control group. Bipolar Disorders 2002;4:243-248
12. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al.Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999;156(11): 1686-1696
13. Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biological Psychiatry 2000;48(6):445-457
14. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. Journal of Affective Disorders 2002;68(2-3):167-181
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM-IV. 4th Edition. Washington DC: APA, 1994.
16. Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. Annals of Pharmacotherapy 2000; 34(7-8):865-867
17. Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR. Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. Journal of Psychopharmacology 2008;Jul 17 [Epub ahead of print]:1-18.
18. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al.A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Archieves of General Psychiatry 2000;57(5):481-489
19. Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G. Lithium for maintenance treatment of mood disorders. Cochrane Database of Systematic Reviews 2002, Issue 4.[Art. No.: CD003013. DOI: 10.1002/14651858.CD003013]
20. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. American Journal of Psychiatry 2005;162:1805-1819.
21. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Annals of Internal Medicine 2000;133:464-470.
22. Esel E, Turan MT, Sofuoglu S, Gonul AS. Improvement of tardive dyskinesia in a bipolar patient with olanzapine. European Psychiatry 2000;15(7):438-439
23. Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL. The Expert Consensus Guidelines for treating depression in bipolar disorder. Journal of Clinical Psychiatry 1998;59(Suppl 4):73-79.
24. Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology and treatment issues. Journal of Affective Disorders 2002;68(1):1-23.
25. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990.
26. Harris C, Barraclough B. Suicide as an outcome formental disorders: a mate-analysis. British Journal of Psychiatry 1997;170:205-228
27. Haslett CD, Kumar S. Can olanzapine be implicated in causing serotonin syndrome?. Psychiatry and Clinical Neurosciences 2002;56(5): 533-535
28. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. The Cochrane Collaboration. Available fromwww.cochrane-handbook.org., [updated February 2008].
29. Keck PE Jr, McElroy SL. Carbamazepine and valproate in the maintenance treatment of bipolar disorder. Journal of Clinical Psychiatry 2002;63(Suppl 10):13S-17S.
30. Kelly RE Jr, Cohen LJ, Semple RJ, Bialer P, Lau A, Bodenheimer A, Neustadter E, Barenboim A, Galynker II. Relationship between drug company funding and outcomes of clinical psychiatric research. Psychological Medicine 2006;361:647-656.
31. Kessler RC, Rubinow DR, Holmes C, Abelson JM, Zhao S. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychological Medicine 1997;27(5):1079-1089
32. Lee C, Wu KH, Habil H, Dyachkova Y, Lee P. Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. Australian and New Zealand Journal of Psychiatry 2006;40(5):437-445.
33. Lykouras L, Gournellis R, Angelopoulos E. Manic symptoms induced by olanzapine. European Neuropsychipharmacology 2001;11(2):97-98
34. Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database of Systematic Reviews 2002, Issue 4.[Art. No.: CD003196. DOI: 10.1002/14651858.CD003196]
35. McElroy SL, Keck PE Jr. Pharmacologic agents for the treatment of acute bipolar mania. Biological Psychiatry 2000;48(6):539-557
36. McEvoy GK. Central Nervous System agents. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1999:1893-1894
37. Murray CJ, Lopez AD. Global mortality, disability and contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349 (9063):1436-1442
38. Nurnberg JI, Gershon ES. Genetics. In: Paykel ES editor(s). Handbook of Affective Disorders. Edinburgh, UK: Churchill Livingston, 1992:131-148
39. Philibert RA, Adam LA, Frank FM, Carney-Doebbling C. Olanzapine usage associated with neuroleptic malignant syndrome. Psychosomatics 2001;42(6):528-529
40. Rendell JM, Gijsman HJ, Keck P, Goodwin GM, Geddes JR. Olanzapine alone or in combination for acute mania. Cochrane Database of Systematic Reviews 2004, Issue 2.[Art. No.: CD004040. DOI: 10.1002/14651858.CD004040]
41. Roefaro J, Mukherjee SM. Olanzapine-induced hyperglycemic nonketonic coma. The Annals of Pharmacotherapy 2001;35(3):300-302
42. Scott J, Pope M. Nonaherence with mood stabilizers: prevalence and predictors. Journal of Clinical Psychiatry 2002;65(5):384-390
43. Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatric Services 1999;50(10):1303-1308
44. Soares-Weiser K, Bravo Vergel Y, Beynon S, Dunn G, Barbieri M, Duffy S, Geddes J, Gilbody S, Palmer S, Woolacott N. A systematic review and economic model of the clinical effectiveness and costeffectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technology Assessment 2007;11:1-226.
45. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Archives of General Psychiatry 1991;48(12):1082-1088
46. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Annals of Internal Medicine 2000;133:455-463.
47. Tohen M, Chengappa R, Suppes T, et al.Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially non-responsive to valproate or lithium monotherapy. Archives of General Psychiatry 2002;59:62-69.
48. Young AH, Hammond JM. Lithium in mood disorders: increasing evidence base, declining use?. British Journal of Psychiatry 2007;191: 474-476.